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Abstract
Background: ClC-7 is a ubiquitous transporter which is broadly expressed in mammalian tissues. It is implied in the
pathogenesis of lysosomal storage disease and osteopetrosis. Because of its endosomal/lysosomal localization it is still
poorly characterized.
Methodology/Principal Findings: An electrophysiological characterization of rat ClC-7 using solid-supported membrane-
based electrophysiology is presented. The measured currents show the characteristics of ClC-7 and confirm its function as a
Cl2/H+-antiporter. We have used rat ClC-7 in CHO cells as a model system to investigate the functionality and cellular
localization of the wt transporter and its variant G213R ClC-7 which is the analogue of human G215R ClC-7 responsible for
autosomal dominant osteopetrosis type II. Our study shows that rat G213R ClC-7 is functional but has a localization defect in
CHO cells which prevents it from being correctly targeted to the lysosomal membrane. The electrophysiological assay is
tested as a tool for drug discovery. The assay is validated with a number of drug candidates. It is shown that ClC-7 is
inhibited by DIDS, NPPB and NS5818 at micromolar concentrations.
Conclusions/Significance: It is suggested that the scenario found in the CHO model system also applies to the human
transporter and that mislocalization rather than impaired functionality of G215R ClC-7 is the primary cause of the related
autosomal dominant osteopetrosis type II. Furthermore, the robust solid-supported membrane-based electrophysiological
assay is proposed for rapid screening for potential ClC-7 inhibitors which are discussed for treatment of osteoporosis.
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Introduction
Members of the family of CLC chloride channels and
transporters have received increasing attention in the last years
because of their important physiological functions and their
implication in pathogenesis. They are, therefore, important targets
for drug discovery. CLC proteins can be divided into a group
localized in the cellular plasma membrane and one localized in the
membranes of intracellular organelles. Interestingly, the members
of the first group are Cl2 channels (ClC-K, ClC-1 and ClC-2)
while the members of the latter group are putative Cl2/H+-
exchangers. Antiport activity was demonstrated for ClC-4 and 5
[1,2], ClC-6 [3] and ClC-7 [4,5]. Some of the CLC transporters in
intracellular membranes are still poorly characterized because of a
lack of sensitivity of conventional electrophysiological techniques
for these transporters. Especially for ClC-7 attempts to bring this
transporter to the plasma membrane for electrophysiological
characterization have failed so far [6].
In this paper we therefore concentrate on ClC-7, a ubiquitous
transporter which is broadly expressed in mammalian tissues [6].
It is found in lysosomes, late endosomes and in the ruffled
membrane of osteoclasts [7,8]. In lysosomes, ClC-7 represents the
major Cl2 pathway [4,9]. Recent findings indicate that the loss of
ClC-7 does not alter lysosomal acidification [7,10] but affects
chloride accumulation [5]. In the ruffled membrane of osteo-
clasts, ClC-7 is essential for bone resorption [8]. The ruffled
membrane lines the resorption lacuna, a specialized acidic
compartment for degradation of the organic bone matrix. The
resorption lacuna is acidified by a specialized V-type H+ ATPase
[11], while ClC-7 might provide a charge compensation for
effective acidification or be involved in the exocytic build-up of
the ruffled border [8]. Indeed, ClC-7 knockout mice display
severe lysosomal storage disease and an impaired bone resorption
phenotype [8,12].
For effective lysosomal function and bone resorption ClC-7
requires a b-subunit, Ostm1. Although ClC-7 is correctly targeted
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to lysosomes, association with Ostm1 enhances ClC-7 stability
probably by protecting it from degradation [10].
Mutations in the CLCN7 gene have been associated with
pathological phenotypes such as different types of osteopetrosis
[13,14,15,16]. For example, the G215R mutation (of human ClC-
7) is the most frequent cause of autosomal dominant osteopetrosis
type II (ADO II) [16,17]. In particular, ADO II osteoclasts have
decreased acidification leading to reduced resorption of mineral-
ized bone [18,19]. The same authors have suggested that
expression and localization of ClC-7 is normal in ADO II patients
implying that this pathology is caused by a reduced functionality of
G215R ClC-7.
In the following we present an electrophysiological character-
ization of rClC-7 using solid-supported membrane-based electro-
physiology (SSM-based electrophysiology) [20]. Investigation of
ClC-7 by standard electrophysiology was not possible due to the
lack of ClC-7 expression in the plasma membrane. We
investigated function and localization of G213R rClC-7 to decide
whether mislocalization or impaired functionality of G215R ClC-7
is responsible for ADO II.
Furthermore, ClC-7 inhibition is discussed for treatment of
osteoporosis [21,22,23,24,25]. However, a robust assay for rapid
screening of drug candidates is still not available. We, therefore,
tested SSM-based electrophysiology as a tool for drug discovery
and validated it with a number of inhibitors.
Materials and Methods
Chemicals
A 1 mM octadecyl-mercaptan (C18-mercaptan, Aldrich, Stein-
heim, Germany) solution in ethanol was used for the incubation of
the gold sensors. The lipid film forming solutions was diphytanoyl-
phosphatidylcholin (Avanti Polar Lipids Inc. Pelham, AL) and
octadecylamin (60:1, wt/wt, 98%, Riedel-DeHaen AG, Seelze
Hannover, Germany). Phloretin, Luteolin, Kaempferol, Tamox-
ifen, Genistein, Quercitin, Furosemide, 2-[3-(trifluoromethyl)ani-
lino]nicotinic acid (NFA), 4,49-diisothiocyanatostilbene-2,29-disul-
fonic acid (DIDS), 5-nitro-2-(3-phenylpropylamino)benzoic acid
(NPPB), p-chlorophenoxy-acetic acid (CPA), p-chlorophenoxy-
propionic acid (CPP), indanyloxyacetic acid 94 (IAA-94) and 9-
anthracene-carboxylic acid (9-AC) were obtained from Sigma-
Aldrich. NS5818 and NS3736 were synthesized at Bioduro,
(Beijing, China).
Molecular Biology
Rat ClC-7 was cloned with a C-terminal GFP-fusionprotein
into pcDNA5/FRT/TO using HindIII and EcoRV. Point
mutations were introduced using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, USA) at position 64 of GFP
(Phe to Leu, primer: 59 - CCA ACA CTT GTC ACT ACT CTC
ACT TAT GGT GTT CAA TGC - 39; 59 - GCA TTG AAC
ACC ATA AGT GAG AGT AGT GAC AAG TGT TGG - 39)
resulting in EGFP and at position 213 of rClC-7 (Gly to Arg,
primer: 59 - CAG ATC AAG TGC TTC CTC AAT AGG GTG
AAG ATC CCC CAG GTG GTG - 39; 59 - CAC CAC GTG
GGG GAT CTT CAC CCT ATT GAG GAA GCA CTT GAT
CTG - 39) resulting in the mutant comparable to the human
G215R. Mouse Ostm1 was obtained in pFROG and could be
transfected directly.
Cell culture
The pcDNA5 constructs were co-transfected with pOG44 into a
Flp-InTM CHO cell line (all InvitrogenTM, Karlsruhe, Germany)
using Effectene (Qiagen, Hilden, Germany). Stable transfectants
were selected by maintaining the cells in HAM’s F-12 medium
(PAA Laboratories, Co¨lbe, Germany), containing 10% FCS, 1%
Penicillin/Streptomycin and 600 mg/ml Hygromycin for 10–14
days. Medium was replaced every 2–3 days. These cell lines,
constitutively and homogeneously expressing the ClC-7 fusion
protein, were additionally transfected with pFROG-mOSTM1
and selected for stable transfectants with 500 mg/ml G418. For
single clone isolation, cells were seeded at a theoretical
concentration of one cell/well in 96well plates. After 7 days,
when single colonies were visible, the clones were expanded and
analyzed for their expression pattern using confocal microscopy.
For membrane preparation, cells were grown in multiple 15 cm
culture dishes. At a confluency of 90–95% cells were harvested
and collected by centrifugation (8006 g). Subsequently, pellets
were flash frozen in liquid nitrogen and stored at 280uC until
preparation.
ClC-Ka expression
Human ClC-Ka (NM_004070) was stably co-expressed with its
b-subunit barttin (NM_057176) in CHO cells using the bipromoter
vector pBudCE 4.1 (Invitrogen). ClC-Ka was inserted via Hind III
and Xba I downstream of the CMV promoter, while Barttin was
inserted after the EF-1a promoter using Kpn I and Xho I. Stable
clones were selected by 150 mg/ml zeocin (Invitrogen). Cells were
cultured and harvested as described before.
EcClC-1 expression
EcClC-1 was expressed in E. coli (BL21 DE3), purified as
described before [26] and reconstituted into liposomes (E. coli
polar lipids, LPR=10) [27].
Membrane preparation
Cell pellets were resuspended in buffer (10 mM TRIS, pH 7.5,
250 mM sucrose, 2 mM dithiothreitol (DTT) and 1 tablet Roche
CompleteTM) and disrupted in a Parr Bomb (Parr Instruments
Deutschland GmbH, Frankfurt/Main, Germany). Total mem-
branes were collected by ultracentrifugation (30 min, 100.0006 g
@ 4uC) and fractionated by density gradient centrifugation (3 h,
100.0006g @ 4uC) [20] using a discontinuous sucrose gradient of
9%, 31%, 45% and 51%. Membrane bands at the gradient
interfaces were collected, diluted 10 fold in resting buffer and
pelleted by ultracentrifugation (30 min, 100.0006 g @ 4uC).
Protein concentration was determined by Bradford assay (BioRad,
Mu¨nchen, Germany). For long term storage, membranes were
flash frozen in resting buffer (with 10% glycerol, 2 mM DTT and
protease inhibitors) and stored at 280uC.
Confocal Microscopy
To investigate the vesicular localization of the wild type (wt) and
mutant ClC-7-EGFP fusion proteins, cells were grown on coverslips
for 24 to 48 hours. After reaching a confluence of 50–80% cells
were incubated with 50 nMLysoTrackerH-Red for 15 min or 1 mM
ER-TrackerTM-Red for 30 min, respectively (Invitrogen). Samples
were analyzed instantaneously with a confocal laser-scanning
microscope (LSM 510, Zeiss) using the argon laser line at 488 nm
for EGFP and a 543 nm HeNe laser for Lyso- and ER-Tracker
excitation. Fluorescence was detected through a 500–550 nm band
pass filter and a 560 nm long pass filter, respectively. Images were
recorded with an Achroplan 636/0.95 W water immersion
objective in multi track mode with sequential excitation of EGFP
and Tracker dye, respectively. LysoTrackerH-Red was prevented
from exposure to broadband illumination before confocal imaging
to prevent photoconversion [28].
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Fluorimetric analysis of membrane fractions
For a quantitative analysis of the membrane fractions the EGFP
fluorescence of the ClC-7 fusion proteins was analyzed using a
microplate fluorescence reader (Lambda Fluoro, BIO-TEK
Instruments, Winooski, USA). Membrane fractions were diluted
to an equal concentration of 1 mg/ml in 50 ml buffer (60 mM
HEPES, pH 7.2, 3 mM CaCl2, 300 mM NaAsp). EGFP was
excited using a 480/20 nm band pass filter, fluorescence emission
was detected through a 530/25 nm band pass filter. The samples
were analyzed in Greiner 96well flat bottom plates, the optical
position was the well bottom.
Western blot
Expression of the ClC-7-EGFP fusion protein and vesicular
distribution of the membrane fractions was tested by Western blot.
15 mg total protein were loaded on a 4–12% bis-tris gel. After
electrophoretic separation, proteins were blotted on a nitrocellu-
lose or PVDF membrane (Invitrogen) and blocked for 1 hour in
5% nonfat dry milk (PBS-T). The blot was incubated with a
rabbit-anti-GFP antibody (Clontech, Mountain View, CA, USA)
(1:100) overnight at 4uC. Lysosome or ER-enriched membrane
fractions were identified, using a monoclonal mouse anti-LAMP-1
(Abcam) and a polyclonal rabbit anti-calnexin antibody (Stressgen,
Ann Arbor, MI, USA). For detection of mOstm1 and ClC-3 rabbit
anti-mOstm1 [10] and anti-ClC-3 [29] antibodies were used. For
detection, appropriate AP (alkaline phospatase) or HRP (horse
radish peroxidase) coupled secondary antibodys (BioRad,
Mu¨nchen, Germany) were used. Finally, AP blots were developed
using AP developer kit (BioRad, Mu¨nchen, Germany). HRP blots
were detected with SuperSignalH West Pico or Femto (Pierce,
Epsom, UK) and developed on film (BioMax, Kodak, Stuttgart)
using a CURIX 60 developer (AGFA, Ko¨ln). Densitometry
analysis of Western blot bands was performed using ImageJ
(NIH, Bethesda, Maryland, USA) [30].
SSM-based electrophysiology
Electrophysiological measurements were performed on a
commercial SURFE2R One instrument (IonGate Biosciences,
Frankfurt, Germany). The experiments were carried out at room
temperature (22uC). After the formation of the SSM [20],
liposomes, membrane vesicles or membrane fragments (set to
equal protein concentrations: ,2 mg/ml) were adsorbed to the
SURFE2R sensors (SSM-area ,7 mm2) using a centrifugation
procedure of 8006g for 45 min. For the ClC-7 measurements the
31/45% membrane fractions were used. Before mounting the
sensors into the SURFE2R One instrument they were kept in Cl2
free buffer (60 mM HEPES, pH 7.2, 3 mM Ca-gluconate,
300 mM Na-aspartate). The solution exchange protocol consisted
of 3 phases with a duration of 2 s each and a flow rate of 250 ml/s:
a flow of nonactivating solution (NA) followed by activating
solution (A) followed by nonactivating solution (NA). Solution A
contained one or both transported substrates of ClC-7 (Cl2, H+).
In the case of Cl2 concentration jumps, NA contained aspartate2
at the same concentration as Cl2 to minimize solution exchange
artifacts. In addition all solutions contained a basic buffer which
was 60 mM HEPES, pH 7.2, 3 mM CaCl2, 300 mM Na-
aspartate at neutral pH. Detailed buffer compositions are given
in the figure legends.
Different buffers or inhibitor concentrations could be applied
automatically using the autosampler of the SURFE2R One
instrument. After changing buffer conditions (eg. pH) the sensors
were incubated for 10–15 minutes before measurement to allow
equilibration of the internal vesicle volume to the buffer
conditions.
Results
Wild type (wt) rat ClC-7 and its G213R variant (the rat
homolog of human G215R) were cloned as fusion proteins with
EGFP. The Flp-InTM expression system was used to generate
stably expressing recombinant CHO-cells. Subsequently, the ClC-
7 b-subunit mOstm1 [10], was co-expressed stably in these cell
lines. Expression and localization were verified using confocal
imaging. While the wt protein was expressed in small vesicular
organelles which nicely co-localized with LysoTrackerH-Red
indicating a lysosomal localization (Fig. 1 A, top row), the
G213R variant was broadly distributed inside the cells and did not
co-localize with LysoTrackerH-Red (Fig. 1 A, middle row).
Instead, it co-localized with ER-TrackerTM-Red indicating
retention in the ER (Fig. 1 A, bottom row).
When the ß-subunit Ostm1 was co-expressed with wt ClC-7, the
EGFP fluorescence and therefore the expression level of ClC-7
increased significantly but localization was not affected in all 12
analyzed clones (Fig. 1 B). In contrast, co-expression of Ostm1
with the G213R mutant altered the ClC-7 localization signifi-
cantly. While the mutant alone showed homogeneous expression
in the ER, the expression pattern became inhomogeneous after co-
expression with Ostm1. In about 30–50% of the cells ClC-7 could
be identified ‘‘re’’-localized in lysosomes while in the rest still ER-
localized expression was observed (Fig. 1 C). In addition, some
cells could be identified where ClC-7 G213R was partly localized
in both compartments, ER and lysosomes. To exclude variations
in the expression level of Ostm1 to be responsible for this
inhomogeneous distribution, 24 single clones of the stably
expressing cell line were analyzed. The described expression
pattern could be observed in almost all of the clones. No clone
with complete lysosomal localization could be observed.
In all cell lines, expression in the plasma membrane could not
be detected. Furthermore, control patch clamp experiments
performed with those cells did not show significant chloride
currents. The absence of ClC-7 expression in the plasma
membrane of recombinant cell lines is in good agreement with
the findings of previous studies [6,7,8,10,31]. However, plasma
membrane expression of ClC-7 in HEK-cells was reported by
Kajiya and coworkers [32].
Due to the lack of ClC-7 expression in the plasma membrane,
standard electrophysiology was not an option. Therefore, SSM-
based electrophysiology was applied using membranes prepared
from CHO cells. In an attempt to separate plasma membrane and
internal membranes, sugar gradient fractionation was used as
described in materials and methods. Western blot analysis of the
different fractions revealed the following results (Fig. 2A):
lysosomes (marker: LAMP-1) were found enriched in fraction
31/45%, while ER (marker: Calnexin) was dominantly present in
45/51%.
The ClC-7-EGFP fusion proteins (,120 kDa) could be detected
by Western blot in the fractions 31/45% and 45/51% (Fig. 2A).
While the wt protein (co-expressed with Ostm1) was enriched in
the lysosomal fraction 31/45% (Densitometric analysis revealed a
relative integral band density of 65%), with only small amounts in
the ER fraction 45/51% (Densitometry: 35%), the G213R mutant
was more equally distributed between these fractions (Densitom-
etry: 51 and 49%) showing a higher presence than wt in the ER
fraction 45/51%.
To quantify the distribution more thoroughly we performed a
fluorimetric analysis of the membrane fractions (Fig. 2B) taking
advantage of the EGFP marker. Wt ClC-7 could be detected
significantly enriched in the lysosomal fraction 31/45% as already
demonstrated qualitatively in western blot analysis. Ostm1 co-
G215R ClC-7 in ADOII
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expression did not significantly alter the distribution. G213R ClC-
7 was detected almost equally distributed between the 31/45%
and 45/51% fractions. Co-expression of Ostm1 slightly changed
the distribution towards 31/45%.
Also the expression behavior of Ostm1 analyzed by western blot
(Fig. 2C) is interesting. In wt ClC-7 cells the cleaved 35 kDa
fragment of Ostm1 [10] could be dominantly detected in the
lysosomal fraction 31/45%, while only small amounts of full length
protein (,70 kDa) were found in the ER fraction 45/51%. In
G213R ClC-7 cells both bands could be detected, with a stronger
population of full length protein in the ER fraction.
Because ClC-3 and ClC-6 have been shown to be shifted
partially into lysosomal fractions upon lack of ClC-7 [9], we tested
our lysosomal fractions (31/45%) for altered expression levels of
other intracellular CLCs upon expression of the different CLC-7
forms. Only ClC-3 could be detected by western blot analysis in
comparable amounts in control CHO, wt ClC-7+Ostm1 and
G213R ClC-7+Ostm1 membranes (Fig. 2D), indicating that ClC-
3 is not responsible for the altered transport activities found in the
different preparations (see below).
To determine ClC-7 protein activity, equal amounts of fraction
31/45% adjusted to the same total protein concentration were
adsorbed to the SSM sensors (see materials and methods) and
transient currents were generated by applying a fast concentration
jump of 30 mM NaCl (Fig. 3). The peak current was used to
quantify the transport activity of ClC-7 [20]. In this configuration
negative currents are indicating the translocation of negatively
charged ions (e.g. Cl2) towards the SSM. In view of the very gentle
method of cell disruption by pressure homogenization [33,34],
lysosomes should still be intact after membrane preparation.
However, only little is known about the adsorption geometry of
membrane samples on the SSM.
While non-expressing Flp-InTM CHO cells yielded only very
small endogenous currents (,150 pA, see Fig. 3A control),
membranes of wt ClC-7 generated currents of 455678 pA (6
sensors). When Ostm1 was co-expressed with wt ClC-7, currents
increased significantly to 787674 pA (6 sensors). Also G213R
ClC-7 membranes yielded detectable currents (292688 pA, 4
sensors), which increased (518672 pA, 5 sensors) when Ostm1
was co-expressed. For a direct comparison of the transporter
activity, the currents obtained with the different preparations were
normalized to the corresponding EGFP fluorescence (Fig. 3C).
Also in the normalized currents the Ostm1 induced increase of
ClC-7 activity was observed in wt and G213R preparations while
the G213R currents were slightly decreased (,30%) compared to
the wt measurements.
In the following, the lysosomal 31/45% membrane fraction of
wt ClC-7-Ostm1 expressing cells was used for further electro-
physiological characterization of ClC-7. For the pH dependence,
transient currents were initiated with a 30 mM NaCl concentra-
tion jump at different pH. Before measurement, sensors were
incubated for 15 min in resting buffer at the desired pH to prevent
pH gradients across the membranes of the adsorbed vesicles.
Currents significantly increased at acidic pH with no saturation
until pH 5.0 (Fig. 4 A).
Ion selectivity was determined for Cl2, Br2 and I2 (Fig. 4 B).
Concentration jumps of Br2 and I2 generate large solution
exchange artifacts due to the strong interaction of the anions with
the lipid headgroups on the SSM [35]. Therefore, transport was
initiated in this case by a proton concentration jump generating a
pH gradient (pH 5.0 inside, pH 7.2 outside of the vesicle) in the
presence of the different anions (30 mM Cl2, Br2 or I2). For
comparison, the same proton concentration jump was applied in
the absence of Cl2 and the resulting peak current (,1 nA)
subtracted. As displayed, ClC-7 is only weakly selective but shows
a significant preference for Cl2 over Br2 over I2.
In addition to the determination of the ion selectivity, the
experiment in Fig. 4B confirms H+-driven anion-transport which
was further examined. Therefore, a 30 mM Cl2 concentration
jump was applied together with inward directed and outward
directed proton gradients and the signals were compared to that
Figure 1. Localization of wild type and G213R ClC-7 in CHO
cells. A: Confocal images of wt ClC-7-EGFP expressing living CHO cells
stained with LysoTrackerH-Red (top row). Images of EGFP fluorescence,
LysoTrackerH-Red fluorescence and the merge of both are shown.
G213R ClC-7-EGFP stained with LysoTrackerH-Red (middle row) and ER-
TrackerTM-Red (lower row). Individual fluorescence images and merge
are shown. B: Co-expression of wt ClC-7-EGFP with its ß-subunit Ostm1.
Compared images were recorded with fixed hardware settings and at
constant experimental conditions. Localization of ClC-7 in Ostm1
expressing cells was not affected but a significantly increased EGFP
fluorescence could be detected. C: Co-expression of G213R ClC-7-EGFP
with Ostm1 partly (,50%) restored lysosomal localization.
doi:10.1371/journal.pone.0012585.g001
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obtained in the absence of proton gradients (pH 7.2). In more
detail: for the favorable pH gradient a combined Cl2 and proton
concentration jump was applied (pH 5.0, no Cl2 inside and
pH 7.2, 30 mM Cl2 outside the vesicle). The same proton
concentration jump was applied in the absence of Cl2 (substituted
by aspartate, amplitude: ,1 nA) and the resulting peak current
subtracted. The resulting difference signal was normalized to a
simple Cl2 concentration jump (pH 7.2, no Cl2 inside and
pH 7.2, 30 mM Cl2 outside the vesicle). For the unfavorable pH
gradient the same procedure was used with pH 9.0 pH inside the
vesicles. For comparison, this was done for different members of
the CLC protein family: the human Cl2 channel ClC-Ka
(+barttin), the well characterized Cl2/H+-antiporter EcClC-1
from E. coli and ClC-7 (Fig. 4C). While pH gradients had no effect
on ClC-Ka (Cl2 channel) activity, EcClC-1 (Cl2/H+-antiporter)
and ClC-7 currents were significantly modulated, depending on
the direction of the gradient (Fig. 4C). Applying the gradient in the
putative transport direction (lower pH inside, higher pH outside
the vesicles) significantly increased (50%) the currents induced by a
fast concentration jump of 30 mM NaCl. Applying the gradient
against the transport direction (higher pH inside, lower pH outside
the vesicles) decreased the currents by 40%.
Specificity of the SSM-based electrophysiological ClC-7 assay
was tested by screening a number of potential chloride channel
inhibitors. Using the SURFE2R One instrument a semi- automatic
screening procedure was established. 16 putative chloride channel
inhibitors were characterized (Table 1) and IC50 values determined
if possible. For that purpose, ClC-7 was activated by concentrations
jumps of 30 mM NaCl in the presence of varying concentrations of
inhibitors in all buffers. Before measurement, sensors were
incubated for 5 min in chloride free buffer, containing the
appropriate inhibitor concentration. IAA-94 and NS3736 generat-
ed large solution exchange artifacts probably due to strong
interaction with the membranes and could, therefore, not be
characterized. Furthermore Quercetin, Genistein, Luteolin and
Phloretin precipitated at high concentrations (.100 mM), prevent-
ing the determination of a complete IC50. Quercetin and Genistein
showed weakly inhibiting effects at 100 mM while CCP, CPA, 9-
AC, Tamoxifen and Kaempferol did not inhibit ClC-7 currents in
the investigated concentration range (,300 mM). Robust IC50
values could be determined for DIDS, NS5818 and NPPB. DIDS
inhibited the currents with an IC50 of 3963.8 mM, NS5818 with
5268.0 mM and NPPB with 15667.8 mM. As an example, the
inhibition graphs for DIDS and NPPB are shown in Fig. 5.
Figure 2. Activity and fractional distribution of wild type and G213R ClC-7. A: Western Blot of membrane fractions against GFP (ClC-7),
LAMP-1 (lysosomes) and Calnexin (ER), showing lysosomes enriched in the 31/45% fraction and ER in the 45/51% fraction. Densitometric analysis of
Western blot bands (Dens.): numbers give relative intergral band densities in % left to right lane. B: Quantitative fluorescence analysis of membrane
fractions. Fractions were adjusted to same total protein concentration. Fractional fluorescence was normalized to the total fluorescence in all samples.
Mean and standard deviation of 2–3 individual preparations. Wt ClC-7 is significantly enriched in 31/45%, while G213R is more equally distributed
between 31/45% and 45/51%. Ostm1 alters G213R localization only slightly. C: Western Blot against Ostm1. Fraction 31/45% and 45/51% of CHO
control cells (CHO), wt ClC-7+Ostm1 (WT) and G213R+Ostm1 (G213R). Arrows: full length Ostm1 (,70 kDa) and cleaved fragment (,35 kDa), asterisk
indicating an unspecific band recognized by the Ostm1 antibody [10]. D: Western Blot against ClC-3 and LAMP-1 in fraction 31/45% of control CHO,
wt ClC-7+Ostm1 and G213R ClC-7+Ostm1.
doi:10.1371/journal.pone.0012585.g002
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Figure 3. Transport activity of ClC-7 using SSM-based electrophysiology. A: Lysosomal fraction 31/45% of wt ClC-7 was adsorbed to the
SSM-sensors and transport was initiated by a rapid concentration jump of 30 mM NaCl. Figure shows representative current traces of repetitive
experiments. Flow protocol: nonactivating (NA) – activating (A) – nonactivating (NA). Solutions: (NA) 330 mM Na-aspartate (NaAsp), 3 mM Ca-
gluconate, 60 mM HEPES pH 7.2, (A) 30 mM NaCl, 300 mM Na-aspartate, 3 mM Ca-gluconate, 60 mM HEPES pH 7.2. B: Transport activity of G213R
ClC-7 using the same protocol as described above. C: Averaged signal amplitudes of all preparations, normalized to individual fractional EGFP
fluorescence. Of each sensor at least 20 signals were recorded, 4–6 individual sensors were investigated for each preparation. Mean and standard
deviation of 4–6 sensors each. For comparison, the corresponding non-normalized current amplitudes are given in the text. Student’s t-test:
* = p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0012585.g003
Figure 4. Electrophysiological characterization of ClC-7. If not otherwise indicated conditions as in Fig. 3. A: pH dependence of ClC-7
transport activity. Transport was initiated by a rapid concentration jump of 30 mM NaCl. Solutions: (NA) 330 mM Na-aspartate, 3 mM Ca-gluconate,
60 mM HEPES, (A) 30 mM NaCl, 300 mM Na-aspartate, 3 mM Ca-gluconate, 60 mM HEPES. HEPES buffer was replaced by MES or TRIS for acidic and
basic conditions, respectively. After buffer exchange to a different pH, sensors were incubated for 15 min to allow equilibration to new conditions. B:
Specificity of ClC-7 anion transport with Cl2.Br2.I2. Transport was initiated by a rapid pH jump (establishing a proton gradient pH 5.0 inside,
pH 7.2 outside of the vesicle) with different anions present in all solutions. Solutions: (NA) 30 mM NaCl (NaBr, NaI), 300 mM Na-aspartate, 3 mM Ca-
gluconate, 30 mM MES, pH 5.0. (A) 30 mM NaCl (NaBr, NaI), 300 mM Na-aspartate, 3 mM Ca-gluconate, 30 mM MOPS, pH 7.2). pH artifacts (same
protocol, but substrate substituted by 30 mM Na-aspartate in A and NA, amplitude: ,1 nA) were subtracted and the resulting currents were
normalized to currents in the presence of NaCl. C: H+-coupled transporter activity of ClC-7 compared to other CLC proteins (ClC-Ka+barttin and
EcClC-1). Transport was initiated by a simultaneous NaCl concentration (30 mM) and pH (DpH,2) jump. Solutions pH 5.0inside–7.2outside: (NA) 30 mM
Na-aspartate, 30 mM MES, pH 5.0, (A) 30 mM NaCl, 30 mM MOPS, pH 7.2. Solutions pH 9.0inside–7.2outside: (NA) 30 mM Na-aspartate, 30 mM TRIS,
pH 9.0, (A) 30 mM NaCl, 30 mM MOPS, pH 7.2. In addition all buffers contained 300 mM Na-aspartate and 3 mM Ca-gluconate. pH artifacts (same
protocol, substrate in A substituted by 30 mM Na-aspartate, amplitude: ,1 nA) were subtracted and resulting currents were normalized to NaCl
initiated currents in the absence of a pH gradient (pH 7.2). P = Student’s t-test, significance level = 0.05.
doi:10.1371/journal.pone.0012585.g004
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Discussion
Solid-supported membrane-based electrophysiology
allows characterization of ClC-7 expressed in CHO cells
and confirms its function as a Cl2/H+-exchanger
This is the first electrophysiological characterization of ClC-7 in
its native environment, i.e. in the lysosomal membrane. Transient
currents observed with membrane preparations of CHO cells
expressing rat ClC-7 show characteristics of ClC-7 transport [4,5]:
(1) strong pH dependence with an increased activity at acidic pH,
(2) ion selectivity Cl2.Br2.I2 and (3) pH-gradient driven anion
transport. In addition, unspecific Cl2 transport inhibitors like
DIDS and NS5818 inhibited the currents with relatively high
affinity (Table 1).
An essential feature of ClC-7 is its function as a Cl2/H+-
exchanger [4,5]. Coupling of ClC-7 Cl2 transport activity to a
proton motive force is demonstrated by two independent
experiments: (1) Anion specific currents driven by a proton
gradient only (Fig. 4B). (2) Modulation of anion specific currents
by a co- and countergradient of protons (Fig. 4C). The latter is a
distinct property of a proton coupled exchanger and is also found
in the related EcClC-1 transporter and not in the Cl2 channel
ClC-Ka (Fig. 4C).
Note that pH regulatory effects cannot be excluded in this
experimental approach. It is known that ClC-Ka currents in two-
electrode voltage clamp measurements [36] are strongly depen-
dent on extracellular pH. However, a pH dependence of the ClC-
Ka currents was not detected in our experiments. This may be
related to the design of our measurements where the external pH
of the membrane vesicles was kept constant at pH 7.2, while the
internal pH was altered (implying right side out oriented
membrane vesicles).
SSM based electrophysiology was essential in this study,
because ClC-7 is expressed in intracellular membranes i.e. late
endosomes and lysosomes, which are not accessible for conven-
tional electrophysiology. Unlike other intracellular transporters
of the CLC family such as ClC-4 and ClC-5, which could be
investigated in oocytes or mammalian cell lines because of a
‘‘spill-over’’ to the plasma membrane at high overexpression
[24,37], ClC-7 related currents could not be detected using whole
cell patch clamp or two-electrode voltage clamp measurements
by different authors in a variety of cell systems [6,7,8,10,31]. This
agrees with our localization studies which show no expression in
the plasma membrane within the limits of detectability. There
are, however, reports of trans-plasma membrane currents in
oocytes, osteoclasts and HEK cells that have been assigned to
ClC-7 [32,38]. The reasons for this discrepancy are still unclear.
In CHO cells wild type ClC-7 resides in lysosomes while
G213R ClC-7 is retained in the endoplasmatic reticulum
Fluorescence of the ClC-7-EGFP fusion protein was used to
check the localization of ClC-7 expressed in CHO cells. In vivo
ClC-7 resides in late endosomes, lysosomes and the ruffled
membrane of osteoclasts [7,8]. It is therefore not surprising to find
wt ClC-7 in CHO cells predominantly in lysosomal membranes
(Fig. 1A). In contrast, G213R ClC-7 shows a different intracellular
distribution suggesting localization in the ER. This is quantita-
tively confirmed by densitometric analysis of ClC-7 western blots
and by fluorimetric investigation of the different membrane
fractions from sugar gradient fractionation. Wt ClC-7 is
preferentially found in the 31/45% fraction which is enriched in
lysosomal membranes while G213R ClC-7 is equally distributed
between the lysosomal 31/45% fraction and the ER fraction 45/
51% (Fig. 2B). Note, that densiometric and fluorimetric results are
in good agreement. Therefore we propose that in CHO cells the
G213R mutation is recognized by the ER-quality control, which
prevents ClC-7 from leaving the ER where it is primarily formed
and being transported to the lysosomal membrane.
Interestingly, Ostm1 significantly changes the expression
pattern of G213R ClC-7, restoring the lysosomal localization to
some extent. In addition, G213R ClC-7 co-expressing Ostm1 is
characterized by a small preference for the lysosomal membrane
Figure 5. Inhibition of ClC-7. Several putative Cl2 channel inhibitors
were tested for inhibition potency (Tab.1). ClC-7 was activated with 30 mM
Cl2 concentration jump while different concentrations of inhibitors (1–
1000 mM) were present in all buffers. The plots show mean inhibition
values and standard deviation of at least 3 independent experiments (5
measurements per concentration each). The data was fitted with a Hill
function, yielding IC50 values of 3963.8 mM (Hill coefficient n=0.6) for
DIDS and 15667.8 mM (Hill coefficient n=1.0) for NPPB.
doi:10.1371/journal.pone.0012585.g005
Table 1. Analyzed Cl2 Channel inhibitors.
Inhibitor Range (mM) Max (%) IC50 (mM)
1 DIDS 1–1000 92 3963.8
2 NS5818 1–300 70 5268.0
3 NPPB 1–1000 90 15667.8
4 Furosemide 3–1000 50 650
5 NFA 1–1000 30 -
6 Quercitin 1–300 # 25 -
7 Genistein 1–300 # 20 -
8 CCP 1–300 0 -
9 CPA 1–300 0 -
10 9-AC 1–300 0 -
11 Tamoxifen 1–300 0 -
12 Kaempferol 1–300 0 -
13 Luteolin 1–300 # 0 -
14 Phloretin 1–300 # 0 -
15 IAA-94 1–300 - *
16 NS3736 1–300 - *
16 different putative Cl2 channel inhibitors were tested. Concentration range
(mM), maximum inhibition (%) and IC50 value (if determinable) is shown. *Could
not be investigated (see text), #Precipitates at high concentrations (.100 mM).
doi:10.1371/journal.pone.0012585.t001
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fraction 31/45% used for the electrophysiological experiments
(Fig. 2 B), resulting in an increase of the measurable currents. On
the level of individual cell clones, an inhomogeneous pattern is
found. Some cells show predominantly lysosomal, some cells
predominantly ER localization. But Ostm1 significantly increases
the lysosomal fraction (Fig. 1C). Because ClC-7 is not dependent
on Ostm1 to reach the lysosomes in general [10], the function of
Ostm1 in our experiments might be to compensate a putative
folding defect caused by the G213R mutation. Thereby the
protein it is no longer recognized by the ER quality control,
resulting in a lysosomal ‘‘relocalization’’. Previous studies indicated
that Ostm1 is cleaved in or on its way to lysosomes [10]. While a
significant amount of full length protein is still found in the ER
fraction of the G213R membrane preparation, the 35 kDa
fragment is observed in both lysosomal fractions, wt and mutant.
Therefore, Ostm1 expression itself does not seem to be the limiting
factor for the ER retained ClC-7 localization.
The G213R ClC-7 mutant is still functional
The currents shown in Fig. 3 demonstrate that the wt as well as
the G213R mutant in the absence and presence of Ostm1 are
functional transporters. Since the currents in Fig. 3C are normalized
to equal protein expression level, these data suggest that mutation as
well as co-expression with Ostm1 modulate the activity of the
individual transporter: the G213R mutation reduces the activity by
,30% while co-expression with Ostm1 enhances the activity by a
factor of ,2. This is a relatively crude estimate, because the
normalization procedure to the expression level using the EGFP
fluorescence of the different preparations introduces a significant
systematic error in the analysis. The error is due to cross
contamination of the lysosomal and ER fractions (compare Fig. 2A
- Calnexin) and the relatively imprecise determination of the protein
concentration using the Bradford assay. However, the fact that the
G213R mutant retains a similar relative activity of ,70% of the wt
in both cases, with and without Ostm1, supports the conclusion that
G213R ClC-7 retains most of the transport activity of the wt.
Interesting is also the enhancement of the normalized
transporter currents by Ostm1 (Fig. 3C). This is observed for
both, the wt and the mutant. Because of the normalization to
equal protein expression, it represents again a property of the
individual transporter and is unrelated to expression density in the
measured membranes. However, in view of the considerable errors
involved in the normalization procedure it remains questionable
whether this represents a true functional enhancement of the
transporter function.
Is ADO II caused by impaired transport activity of ClC-7 or
by a lack of lysosomal ClC-7?
Mutations in ClC-7 or its b-subunit Ostm1 lead to severe
pathological phenotypes [39]. In neurons, a disrupted lysosomal
function leads to accumulation of lysosomal storage material and
neurodegeneration [7]. Another example is the decreased acidifi-
cation of the resorption lacuna in osteoclasts. This causes reduced
resorption of mineralized bone as is the case in ADO II [18,19].
Mutations can cause a lack of function by direct impairment of
protein activity, by a lack of protein expression or by its incorrect
trafficking. It has been suggested previously [19], that expression
and localization of ClC-7 is normal in ADO II patients implying
that this pathology is caused by a reduced functionality of G213R
ClC-7. Our data seem to challenge this hypothesis although they
are strictly valid only for rat ClC-7 and for the CHO expression
system. On the other hand, rat ClC-7 is 96% identical to the
human protein [8] and eukaryotic protein trafficking is believed to
follow similar laws in different mammalian cell types.
As shown above, the transporter function of G213R ClC-7 is
not abolished. At the same time localization studies demonstrate
that G213R ClC-7 is retained in the ER while the wt is correctly
targeted to the lysosomal membranes (Fig. 1A). Applied to ADO II
this suggests that G213R related ADO II is predominantly caused
by defective trafficking, while the impaired transporter activity of
the mutant ClC-7 plays only a marginal role. Interestingly,
osteoclasts from ADO II patients show a reduced total resorption
pit area but the area of the individual pits was the same [18]
implying that some of the ADO II osteoclasts are still fully
competent of bone resorption while others are inactive. This
agrees with the inhomogeneous cell population found in G213
ClC-7 CHO cells (Fig. 1C) where in some cells predominantly the
correct lysosomal localization is found while in others the
transporter is retained in the ER.
SSM-based electrophysiology for drug discovery
Because of its involvement in bone pathology, ClC-7 is an
interesting target for drug discovery. For example, inhibitors of ClC-
7 are under discussion for the treatment of osteoporosis [22,23,25].
CHO cells were chosen because they produced only small
background currents due to their low level of endogenous Cl2
conductance. Cl2 transporters like ClC-5 are not at all expressed in
CHO [40] and also the tissue specific members of the ClC family like
ClC-6 are not expected in CHO. ClC-3, which could be detected in
western blot analysis (Fig. 2D) (possibly because of endosomal
contamination of the membrane fractions) could together with
endogenous ClC-7 be responsible for the small endogenous
background currents in the CHO control preparations (Fig. 3A).
Assay quality is commonly estimated by the Z’- factor, with a
Z’.0.5 being considered an ‘‘excellent’’ assay [41]. Our SSM-
based electrophysiological assay for ClC-7 yielded a Z’ = 0.78. To
validate the assay a few plausible inhibitor candidates for ClC-7
were tested but no highly selective and high affinity compound was
found that would be suitable as a drug candidate. Comparison of
the determined inhibitor profile to that of ClC-3 and other
chloride channels and transporters supports the assignment of the
transient currents to ClC-7. ClC-3 is blocked by phloretin and
tamoxifen, which was not the case in our experiments [42,43].
Furthermore, our findings are in good agreement with osteoclast
acidification and resorptions studies [44], where NPPB and the
compound NS5818 [19,45] could be identified as relatively potent
inhibitors, while 9-AC, CPA and CPP had no effect on the
osteoclast activity.
In conclusion, the inhibition study proves the suitability of SSM-
based electrophysiology for screening of ClC-7 inhibitors. Among
the small number of tested compounds no promising drug
candidate for the inhibition of ClC-7 could be identified. For a
realistic chance of detecting drug candidates larger compound
libraries have to be screened using dedicated equipment which is
now commercially available [20].
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